Meet MTRC at ISPOR Europe 2025: Booth #1201

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of October 20th, we plan to work on 21 projects. Review the complete list of planned activities in this post.

MTRC has released a White Paper titled "Evidence requirements for medical devices in the “New methods” framework in Norway”. This White Paper provides an opportunity to learn about the evidence requirements related to the 'New Methods' framework from the 5 recent med tech assessments in Norway. The review is followed by recommendations on evidence generation and will be useful for medical device manufacturers seeking market access in Norway, as well as HTA professionals and policymakers interested in the Norwegian evaluation framework.

Meet MTRC at the European Digital Technology and Software Conference in Rotterdam. Don’t miss Dr. Borisenko’s presentation, “Healthcare Market Access and Reimbursement in the Age of AI,” on Thursday, 30 October 2025, from 12:15 PM to 1:15 PM CET. The session will deliver key insights on typical market access challenges and opportunities for AI technologies across different technology segments (health apps, digital platforms, and imaging AI), market access strategies, evidence requirements from a market access perspective, innovative payment schemes, and case studies of successful AI technologies.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of October 06th, we plan to work on 20 projects. Review the complete list of planned activities in this post.

MTRC has released a White Paper titled "Innovation Funding (Forfait Innovation) for Medical Technologies in France”. This White Paper provides a comprehensive overview of the Innovation Funding (Forfait Innovation) program. It describes the scheme’s objectives, eligibility criteria, funding structure, and the decision-making process with regulated timelines. It also outlines the roles of stakeholders, clinical and economic evidence requirements, and the outcomes of applications since the program’s launch in 2015. In addition, this document presents a case study of the METAglut1 test, illustrating the pathway from Innovation Funding to permanent reimbursement inclusion under NABM.